Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Joi + Blokes vs Roboclinic

Joi + Blokes
Graded #203

Higher grade

vs+1.0999999999999943
Roboclinic
Graded #234

Lower grade

The verdict

Joi + Blokes takes it — 66.1/100 to 65/100, but only just.

Joi + Blokes grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Joi + Blokes is a hormone-first telehealth platform with parallel programs for women (Joi) and men (Blokes), now expanded to compounded GLP-1s for weight loss. Roboclinic is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEven
50
50
Dose & formulationRoboclinic +11
64
75
Clinical oversightJoi + Blokes +2
86
84
Labs & monitoringJoi + Blokes +34
87
53
FulfillmentEven
75
75
Contract termsRoboclinic +27
20
47
Joi + Blokes · left barRoboclinic · right bar

The numbers

MetricJoi + BlokesRoboclinic
WeighScore66.1/10065/100
GradeCC
Scorecard rank#203#234
Semaglutide$199/mo (promotional rate, quarterly plan, compounded)$179/mo (12-month plan, compounded)
Tirzepatide$299/mo (quarterly plan, compounded)$299/mo (12-month plan, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
Joi + Blokes

Graded #203 · C

Strengths

  • Separate programs for women (Joi) and men (Blokes) — most GLP-1 telehealth is gender-agnostic
  • Trustpilot 4.6/5 from 1,254+ reviews — among the strongest review signals in the category
  • Monthly price includes medication, dosing support, clinician consults, and health coaching
  • Integrated hormone + GLP-1 programs help patients on testosterone or perimenopausal protocols
  • First-month discount ($99 sema / $149 tirz) lowers the barrier to trying GLP-1s

Where it loses points

  • Billed quarterly — a 3-month commitment up front, not month-to-month
  • Different pricing in NY and NJ — verify your state's cost before committing
  • Per-state availability isn't listed; it's zip-code gated behind signup
  • Months 2+ cost more ($199 sema / $299 tirz) than the headline intro price
  • No FDA-approved Wegovy — compounded only on the GLP-1 side; Zepbound carries a separate visit fee
Roboclinic

Graded #234 · C

Strengths

  • Compounded semaglutide from $179/mo and tirzepatide from $299/mo on 12-month plans
  • One all-in price bundles the provider consult, prescription, and delivery
  • Offers both injectable and oral (tablet) compounded semaglutide
  • 'Same price, every dose' means your cost does not rise as the dose increases
  • AI-first intake with board-certified provider review; no insurance necessary

Where it loses points

  • Lowest rates require a 12-month plan; month-to-month runs $299/mo (semaglutide) to $399/mo (tirzepatide)
  • Individual compounding pharmacies are not named; fulfillment is routed through OpenLoop Health
  • No published per-state list; site claims 'all 50 states, restrictions apply' and gates doctor review by region
  • Refunds limited to your most recent billing cycle; none for used or partially used periods
  • Operated by BrickFi, Inc., a newer brand with limited independent track record

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard